Spot Trading’s ImmunityBio IBRX Stock Holding History

Spot Trading’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-303	Closed	-$2K	–	3542
2016 Q1	$2K	Buy	+303	New	+$2.86K	﹤0.01%	3296

Other funds holding IBRX

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Callan Capital La Jolla, California $1.35B AUM 8.35% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Spot Trading's IBRX Position: Q2 2016 in Review

Spot Trading sold out of ImmunityBio (IBRX) in Q2 2016, closing a stake of 303 shares — an estimated $2K sold.

Spot Trading first reported a position in IBRX in Q1 2016 and held it in 1 quarter. The position peaked at $2K in Q1 2016. 62 funds tracked by Wall St. Rank hold IBRX as of Q2 2016.

Spot Trading reported no remaining ImmunityBio position as of Q2 2016 after selling out during the quarter.
Spot Trading sold 303 ImmunityBio shares in Q2 2016, an estimated $2K.
Spot Trading first reported a position in ImmunityBio in Q1 2016 and held it in 1 quarter.
Spot Trading's ImmunityBio position peaked at $2K in Q1 2016.
62 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2016.

Based on Spot Trading's 13F filing for Q2 2016, filed 2 Aug 2016.